BAYRY News and Press, Bayer AG ADR From 11/20/23

2023-11-20 07:14:14 ET More on Bayer Breaking Up Bayer? Probably Not! Bayer Aktiengesellschaft 2023 Q3 - Results - Earnings Call Presentation Bayer Aktiengesellschaft (BAYZF) Q3 2023 Earnings Call Transcript EU to extend glyphosate use for 10 more years after...

2023-11-16 13:09:47 ET More on Bayer Breaking Up Bayer? Probably Not! Bayer Aktiengesellschaft 2023 Q3 - Results - Earnings Call Presentation Bayer Aktiengesellschaft (BAYZF) Q3 2023 Earnings Call Transcript Bayer pulling lymphoma drug from US market over fai...

2023-11-16 12:35:07 ET Summary Recursion Pharmaceuticals, Inc. proof-of-concept data, from the phase 2 SYCAMORE study using REC-994 for the treatment of patients with Cerebral Cavernous Malformation, expected in the 2nd half of 2024. Safety and preliminary efficacy data, from the ...

2023-11-14 06:41:42 ET Summary Teck Resources is selling its coal business to Glencore, Nippon Steel and POSCO. Bayer is withdrawing its drug Aliqopa from the US market after a failed study. Boeing is increasing production of Patriot missile sensors to meet rising demand. ...

2023-11-13 17:03:00 ET More on Bayer Breaking Up Bayer? Probably Not! Bayer Aktiengesellschaft 2023 Q3 - Results - Earnings Call Presentation Bayer Aktiengesellschaft (BAYZF) Q3 2023 Earnings Call Transcript Bayer considering breakup but not immediate three-w...

2023-11-10 10:56:34 ET Summary Bayer is reporting rather terrible third quarter results, although currency effects had a huge negative impact on the top line. Additionally, Bayer is currently discussing several options how to proceed with the business – including the possib...

Bayer AG ADR (BAYRY) is expected to report $0.28 for Q3 2023

2023-11-08 10:19:05 ET Bayer Aktiengesellschaft (BAYZF) Q3 2023 Earnings Conference Call November 08, 2023 08:00 AM ET Company Participants Jost Reinhard - Senior Vice President & Head-Investor Relations Bill Anderson - Chief Executive Officer Wolfgang Nickl ...

2023-11-08 07:33:42 ET More on Bayer Bayer: Good Value For Money Bayer: Undervalued With Clear Catalysts Bayer: Still A Strong Buy Despite Lowered Guidance For further details see: Bayer considering breakup but not three-way split, CEO Anderson says

2023-11-08 02:03:18 ET More on Bayer AG Bayer Stock: Good Value For Money Bayer: Undervalued With Clear Catalysts Bayer: Still A Strong Buy Despite Lowered Guidance Bayer slapped with $332M jury verdict in Roundup cancer trial Twist Bioscience inks an...